The Dermatology Office Wants 200 Jars for the Back Room
A Missouri community pharmacy compounds for a local dermatology practice. The practice asks for 200 jars of a 0.05% tretinoin / 4% hydroquinone cream "for office use," to be handed out after laser procedures, delivered next week. No patient names are supplied. Separately the pharmacy is making a 100 mL oral antibiotic suspension for a 4-year-old whose prescription is on file, and it has a 100 g jar of a water-containing topical gel compounded from bulk powder. The pharmacy recently found a cheaper bulk hydroquinone supplier that is not FDA-registered but provides a certificate of analysis, and wants to switch.
1. Can the pharmacy prepare the 200 jars for office use as a 503A pharmacy?
Read the worked answer
No. A Section 503A pharmacy may compound only in response to a patient-specific prescription (or a limited quantity in anticipation of receiving prescriptions, based on an established, documented history of such prescriptions). Two hundred jars for a prescriber's back room is manufacturing/distribution, not dispensing:
- There are no identifiable patients and no prescriptions.
- Distributing compounded products to a prescriber for the prescriber to dispense is the model of a 503B outsourcing facility, which must register with FDA and meet CGMP and other requirements. A 503A pharmacy cannot step into that role informally.
- A 503A pharmacy's out-of-state distribution is separately capped (no more than 5% of its total prescription orders), which this arrangement would also strain.
A lawful path: the practice writes prescriptions for named patients, or the pharmacy refers the practice to a registered 503B facility. The pharmacy should also confirm the cream is not essentially a copy of a commercially available combination product dispensed regularly - if it is, routine compounding of it is not permitted under 503A, though a prescriber's documented determination of a clinical difference for a specific patient changes that analysis.
2. How should beyond-use dates be assigned for the oral suspension and the water-containing topical gel?
Read the worked answer
Absent a stability study or a documented manufacturer's basis, apply the default (never-exceed) limits from USP <795>:
- Water-containing oral formulation (the antibiotic suspension): 14 days, refrigerated.
- Water-containing topical/dermal formulation (the gel): 30 days, with appropriate storage.
- Nonaqueous dosage forms: up to 180 days.
These are ceilings, not targets: if the manufacturer's package insert gives a shorter in-use period once the commercial product is reconstituted or opened, the shorter date controls. The compounding record must document the formula, sources, lot numbers, the assigned beyond-use date, and the basis for it (default limit vs. stability data), and the dispensed label must carry the beyond-use date and storage instructions. Handing the practice 200 jars with a 30-day date would also have failed the previous question - a BUD that expires before an office-use supply could ever be consumed is a tell that the arrangement is not dispensing.
3. May the pharmacy use bulk hydroquinone from the non-FDA-registered supplier? What should the pharmacist require?
Read the worked answer
No. For 503A compounding, a bulk drug substance must:
- Comply with an applicable USP or NF monograph;
- Be manufactured by an establishment registered with FDA; and
- Be accompanied by valid certificates of analysis from the manufacturer.
A cheap certificate of analysis from an unregistered supplier does not satisfy the registration requirement, and the COA alone does not prove the material meets the monograph. The pharmacist should:
- Verify the supplier's FDA registration status and obtain the COA, keeping both in the compounding file.
- Confirm the substance's identity, strength, purity and quality before use.
- If the only available source is unregistered, decline to compound that product and tell the prescriber why - a substituted, unverified API is a patient-safety exposure, and the pharmacy's sterile/nonsterile compounding records are discoverable.
The cost argument never overrides the sourcing requirement; the prescriber's patient has no way to evaluate the supply chain.